EUVIMEDEUVIMED entdecken
Crossref

Eflornithine (Iwilfin) for High-Risk Neuroblastoma

The Medical Letter on Drugs and Therapeutics · 2024

DOI: 10.58347/tml.2024.1702f ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2024. Hauptthemen laut MEDLINE: Neuroblastoma, Eflornithine. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Eflornithine (Iwilfin – US WorldMeds), an oral ornithine decarboxylase inhibitor, has been approved by the FDA to reduce the risk of relapse in children and with high-risk neuroblastoma who had at least a partial response to prior multiagent, multimodality therapy, including anti-GD2 immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaEflornithineHumansAntineoplastic Agents

Stichwörter der Autor:innen

Iwilfinadverse effectsdosageefficacyeflornithinelactationneuroblastomapregnancysafety

Substanzen

EflornithineAntineoplastic Agents

Zitieren

APA

(2024). Eflornithine (Iwilfin) for High-Risk Neuroblastoma. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2024.1702f

Vancouver

Eflornithine (Iwilfin) for High-Risk Neuroblastoma. The Medical Letter on Drugs and Therapeutics. 2024. doi:10.58347/tml.2024.1702f

BibTeX
@article{euvimed2024,
  title = {Eflornithine (Iwilfin) for High-Risk Neuroblastoma},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2024},
  doi = {10.58347/tml.2024.1702f}
}
Kostenlos starten →